Edwards Lifesciences (EW) Expected to Post Quarterly Earnings on Wednesday

Edwards Lifesciences (NYSE:EW) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.7370 per share and revenue of $1.68 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Edwards Lifesciences Stock Down 0.1%

Edwards Lifesciences stock opened at $91.91 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences has a 12 month low of $74.66 and a 12 month high of $96.29. The stock has a market capitalization of $52.92 billion, a PE ratio of 52.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.85. The business has a 50 day simple moving average of $88.15 and a 200-day simple moving average of $85.43.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,428,912.10. This trade represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock valued at $451,596 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EW shares. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Barclays raised Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, October 7th. Jefferies Financial Group boosted their price objective on Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Evercore reiterated an “outperform” rating on shares of Edwards Lifesciences in a research report on Friday, October 23rd. Finally, Mizuho increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $101.16.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.